Surrozen, Inc. $SRZN Stock Holdings Lifted by Stonepine Capital Management LLC

Key Points

• Stonepine Capital Management LLC has increased its stake in Surrozen, Inc. by 108.3%, now owning 285,782 shares, representing approximately 3.2% of its total holdings.
• Surrozen's stock had a one-year low of $5.90 and a one-year high of $18.17, with a current market cap of $96.04 million.
• HC Wainwright has maintained a "buy" rating on Surrozen, setting a target price of $32.00, while analysts predict it will record -8.49 EPS for the current fiscal year.

Stonepine Capital Management LLC increased its holdings in Surrozen, Inc. (NASDAQ:SRZN - Free Report) by 108.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 285,782 shares of the company's stock after buying an additional 148,582 shares during the period. Surrozen comprises approximately 3.2% of Stonepine Capital Management LLC's holdings, making the stock its 7th biggest position. Stonepine Capital Management LLC owned 8.71% of Surrozen worth $3,332,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company's stock valued at $321,000 after buying an additional 4,630 shares during the period. Trustees of Columbia University in the City of New York acquired a new position in shares of Surrozen in the 4th quarter valued at about $688,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Surrozen in the 4th quarter valued at about $928,000. Nantahala Capital Management LLC lifted its position in Surrozen by 4.7% in the 4th quarter. Nantahala Capital Management LLC now owns 196,023 shares of the company's stock valued at $2,813,000 after purchasing an additional 8,817 shares during the last quarter. Finally, Vivo Capital LLC bought a new stake in Surrozen in the 1st quarter valued at about $3,032,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen Stock Performance

Shares of SRZN stock traded down $0.03 during midday trading on Friday, reaching $11.66. 16,991 shares of the company were exchanged, compared to its average volume of 19,488. The company's 50 day moving average price is $9.60 and its two-hundred day moving average price is $9.85. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $18.17. The company has a market cap of $99.88 million, a P/E ratio of -0.81 and a beta of 0.60.

Surrozen (NASDAQ:SRZN - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.23) by $0.09. Surrozen had a negative net margin of 274.42% and a negative return on equity of 545.43%. The business had revenue of $0.98 million for the quarter. As a group, sell-side analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and issued a $32.00 price objective on shares of Surrozen in a research report on Monday, May 12th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Surrozen presently has an average rating of "Buy" and an average target price of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.